2019
DOI: 10.1101/816066
|View full text |Cite
Preprint
|
Sign up to set email alerts
|

In Vivo Neuroregeneration to Treat Ischemic Stroke in Adult Non-Human Primate Brains through NeuroD1 AAV-based Gene Therapy

Abstract: Stroke is a leading cause of death and disability but most of the clinical trials have failed in the past, despite our increasing understanding of the molecular and pathological mechanisms underlying stroke. While many signaling pathways have been identified in the aftermath of stroke, the majority of current approaches are focusing on neural protection rather than neuroregeneration. In this study, we report an in vivo neural regeneration approach to convert brain internal reactive astrocytes into neurons thro… Show more

Help me understand this report
View published versions

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

1
5
0

Year Published

2020
2020
2021
2021

Publication Types

Select...
4
2

Relationship

5
1

Authors

Journals

citations
Cited by 8 publications
(6 citation statements)
references
References 63 publications
(97 reference statements)
1
5
0
Order By: Relevance
“…3). Therefore, these astrocytic lineage tracing experiments in Aldh1l1-CreER T2 mice clearly demonstrate that astrocytes can be directly converted into neurons by NeuroD1, consistent with our series of publications in recent years(31)(32)(33)(59)(60)(61)(62).…”
supporting
confidence: 91%
“…3). Therefore, these astrocytic lineage tracing experiments in Aldh1l1-CreER T2 mice clearly demonstrate that astrocytes can be directly converted into neurons by NeuroD1, consistent with our series of publications in recent years(31)(32)(33)(59)(60)(61)(62).…”
supporting
confidence: 91%
“…GC is a co-founder of NeuExcell Therapeutics Inc. This manuscript has been released as a pre-print at bioRxiv (Ge et al, 2019).…”
Section: Plasmid Construction and Aav Virus Productionmentioning
confidence: 99%
“…injection of AAV will use a much higher dose in the circulation to reach a reasonable concentration in the brain that may trigger severe inflammation in the liver, spleen, kidney, etc. We have already performed non-human primate experiments where intracranial injection of AAV resulted in a nice viral infection in every monkey injected (Ge et al, 2019), suggesting that pre-existing AAV antibodies, if any, in the monkey brain may not be sufficient to antagonize the AAV injected locally.…”
Section: Implications For Future Clinical Translationsmentioning
confidence: 99%